Chiron misses Street

CHIR reported second quarter adjusted EPS of $0.08, missing the Street's consensus estimate by $0.08 and down 60% from $0.20 in the second quarter of 2004. The quarter's figure includes $27 million in remediation and legal costs associated with Fluvirin and $15 million in charges related to CHIR's inability to supply Begrivac in the coming flu season.

Second quarter sales came in at $304 million, up 8% from $281 million in the second quarter of 2004. CHIR recorded no sales of influenza vaccines. Blood testing revenues came in at $133 million, up 16% from $115 million in the same period in 2004. ...